Showing 1461-1470 of 10595 results for "".
From Flare to Farewell: The IBD Care Playbook for Advanced Practice Providers
https://reachmd.com/programs/cme/from-flare-to-farewell-the-ibd-care-playbook-for-advanced-practice-providers/39248/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease
https://reachmd.com/programs/cme/novel-therapies-manage-episodes-patients-parkinsons-disease/11792/Which of your patients with Parkinson’s disease might benefit from emerging pharmacotherapies?Fluid Biomarkers in Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/fluid-biomarkers-in-multiple-sclerosis/36255/Fluid biomarkers may allow for improvement in diagnosis, prognostication, and monitoring of disease activity and treatment response in multiple sclerosis while reducing reliance on imaging.Targeting CKD-aP at the Source: Key Mechanisms and Treatments
https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/Explore CKD-associated pruritus mechanisms, clinical impact, and evidence-based treatments, including kappa-opioid receptor agonists.Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
https://reachmd.com/programs/cme/case-based-approach-managing-hyperkalemia-in-patients-with-ckd-and-heart-failure/37617/Explore expert tips on using potassium binders to manage hyperkalemia and maintain GDMT in patients with CKD and heart failure.IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
https://reachmd.com/programs/cme/ibd-masterclass-foundations-of-pathophysiology-and-targeted-therapy/49149/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
https://reachmd.com/programs/cme/stuck-on-antihistamines-for-managing-patients-with-ckd-ap-time-to-reconsider/37607/Apply clinical practice guideline recommendations in managing patients with chronic kidney disease-associated pruritus (CKD-aP).Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
https://reachmd.com/programs/cme/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/Join Drs. Daga and Lafayette for a case discussion exploring the optimal use of complement inhibitor therapy in a pediatric patient with C3 glomerulopathy.The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/Experts explain how emerging clinical data and novel therapeutic strategies in HNSCC can expand our treatment armamentarium and improve patient outcomes.